rs770248150
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
|
16618717 |
2006 |
rs770248150
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
|
19114683 |
2009 |
rs770248150
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
18316791 |
2008 |
rs770248150
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
20921465 |
2010 |
rs770248150
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
|
19679400 |
2009 |
rs770248150
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
20921465 |
2010 |
rs770248150
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
|
19679400 |
2009 |
rs770248150
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
|
16361624 |
2005 |
rs770248150
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
|
16361624 |
2005 |
rs770248150
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs770248150
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
|
20921462 |
2010 |
rs770248150
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs770248150
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs770248150
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
|
16618717 |
2006 |
rs770248150
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
|
19114683 |
2009 |
rs770248150
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
|
20921462 |
2010 |
rs770248150
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
18316791 |
2008 |